Valeant Pharma (VRX) Misses Q2 EPS by 10c; Boosts FY15 Outlook

Valeant Pharma (NYSE: VRX) reported Q2 EPS of $2.46, $0.10 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $2.73 million, versus $2.04 million reported last year.

Valeant Pharma sees Q3 2015 EPS of $2.60-$2.70. Valeant Pharma sees Q3 2015 revenue of $2.6-2.8 billion.

Valeant Pharma sees FY2015 EPS of $11.50-$11.80, versus prior guidance of $10.90-$11.20. Valeant Pharma sees FY2015 revenue of $10.7-11.1 billion, versus prior guidance of $10.4-10.6 billion.

For earnings history and earnings-related data on Valeant Pharma (VRX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown